VahatiCor Appoints Harry D. Rowland as Chief Executive Officer

Before joining VahatiCor, Harry D. Rowland served as CEO and President of Endotronix. He led the development, and launch of the Cordella Pulmonary Artery Sensor and Heart Failure System. During his leadership, the company raised more than $150 million and expanded to over 150 employees.

Rowland also managed the PROACTIVE-HF clinical trial through FDA approval and commercial launch. After Endotronix was acquired by Edwards Lifesciences in 2024, he continued to support key regulatory, and market expansion milestones, including CMS coverage and CE Mark approvals.

VahatiCor is currently enrolling patients in the SERRA-I early feasibility study for its A-FLUX Reducer System while also preparing for the SERRA-II study and advancing its engineering, clinical, regulatory, and commercial programs.

Harry D. Rowland brings experience leading cardiovascular medical technology companies through clinical development, regulatory approval, and commercialization, which will support VahatiCors next stage of growth.

Coronary Microvascular Dysfunction affects millions of people who continue to experience chest pain and related symptoms even without major blockages in their coronary arteries. VahatiCor is developing the A-FLUX Reducer System, a catheter-based treatment designed for patients whose symptoms continue despite medical therapy. The A-FLUX Reducer System is still investigational and has not yet been approved by the U.S. Food and Drug Administration for commercial use.

Read More:Xsolla Partners With Tenjin to Connect Web Shop Revenue

“Harry is the right leader for VahatiCor at this pivotal stage, when breakthrough technology requires disciplined execution,” said Brian R. Smith, Managing Director at S3 Ventures. “A-FLUX® represents a substantial opportunity to reach a large, underserved patient population, and Harry brings the proven ability to build the team, clinical evidence, and operational foundation needed to move that opportunity forward. His leadership brings to VahatiCor the operating strength and focus required for its next phase of growth.”

“I was immediately drawn to VahatiCor as a promising alternative treatment option for patients suffering from persistent chest pain. The A-FLUX hourglass-shaped implant, placed in the coronary sinus, is designed to increase blood flow to the microvasculature, reducing this pain and improving overall quality of life,” said Harry Rowland, CEO of VahatiCor. “I’m excited to join the talented VahatiCor team and partner with physician collaborators to grow the evidence to support clinical use and help patients in need.”

About VahatiCor

Founded in 2021, VahatiCor develops medical technology for patients with Coronary Microvascular Dysfunction, a condition that affects millions of people who experience chest pain even without major artery blockages. Its A FLUX Reducer System is designed to offer a new treatment option for patients with ongoing symptoms such as chest pressure, and discomfort, helping improve care for those with limited treatment choices.

Read More:Fidium Names Dennis L. Randolph, Jr. Chief Financial Officer